The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Inspired by a project carried out in Belgium and Luxembourg evaluating the effectiveness of the electronic patient information leaflet and the key principles created by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), EAHP conducted a survey on the use of electronic product information (ePI) in European hospitals. The survey was carried out in cooperation with the Inter-Association Task Force for electronic product information composed out of Medicines for Europe, EFPIA (European Federation of Pharmaceutical Industries and Associations) and AESGP (Association of the European Self-Care Industry) from March to April 2021 and targeted hospital pharmacists in 36 European countries, ultimately receiving 534 answers.
The main findings of the survey are the following:
Almost 60% of respondents reported that healthcare professionals use the digital version when they wish to obtain information on a medicine. Hospital pharmacists (93%) are those using most frequently the digital format of the product information followed by physicians (71%) and nurses (43%). Given that the survey only targeted hospital pharmacists, it should be noted that the presumed behaviour of both healthcare professionals and patients are always the opinion of the hospital pharmacists’ answering the survey.
The survey reveals that patients are usually not provided with paper package leaflets and only 21% of respondents reported that medicines information is provided orally to patients. In this regard, the majority of respondents see the potential of further informing patients by giving them access to ePI. It would also ensure that the information accessed is up to date.
The report nevertheless acknowledged that some challenges should be addressed concurrently, especially equipping hospitals with the appropriate IT infrastructure while at the same time taking into account the structural preconditions of hospitals in Europe regarding the technical equipment to use ePI in daily practice.
Read the survey report HERE
Access the infographic HERE
Joint statement on Electronic Product Information (ePI)
Ahead of the future co-legislators’ negotiations on the European Commission’s Proposals for a revision of the pharmaceutical legislation in the European Union, EAHP -together with community pharmacists, doctors, nurses, hospitals and healthcare services, consumers, older people, health insurance funds and not-for-profit health mutuals associations– calls for inclusive provisions on the use of electronic product information leaflets (ePI) as a complementary tool and not a replacement of packaged leaflets.
The signatories of the joint statement call upon the co-legislators to:
- Contribute to an inclusive society, without enacting discriminatory rules that increase the digital divide and limit individuals’ choice
- Recognise the importance of the package leaflet as a key tool for information accessibility
- Balance the advantages and disadvantages of ePI
- Protect patients’ privacy and guarantee that the information is not used for commercial purposes
- Listen to patients and other end users as an evidence-base for action
Read the full joint statement HERE.